Published in Clin Cancer Res on December 22, 2009
Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase. PLoS One (2012) 1.06
Novel and reversible mechanisms of smoking-induced insulin resistance in humans. Diabetes (2012) 1.03
IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. Oncogene (2012) 1.00
Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. Oncotarget (2015) 0.91
TRAF4 is a critical molecule for Akt activation in lung cancer. Cancer Res (2013) 0.90
Mammalian target of rapamycin and head and neck squamous cell carcinoma. Head Neck Oncol (2011) 0.86
Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway. J Cancer Res Clin Oncol (2011) 0.84
The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells. Oncotarget (2015) 0.84
Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells. Clin Exp Metastasis (2013) 0.81
The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals (Basel) (2012) 0.81
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. PLoS One (2015) 0.79
Chemoprevention of lung cancer: prospects and disappointments in human clinical trials. Cancers (Basel) (2013) 0.78
Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish. Dis Model Mech (2013) 0.78
Phosphorylated 4E-binding protein 1 expression is associated with poor prognosis in small-cell lung cancer. Virchows Arch (2015) 0.78
Optimizing mouse models for precision cancer prevention. Nat Rev Cancer (2016) 0.77
Analysis of miRNA profiles identified miR-196a as a crucial mediator of aberrant PI3K/AKT signaling in lung cancer cells. Oncotarget (2016) 0.77
When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow? Curr Pharmacol Rep (2015) 0.77
Early and delayed intervention with Rapamycin prevents NNK-induced lung adenocarcinoma in A/J mice. Oncol Rep (2015) 0.77
Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities. Int J Mol Sci (2014) 0.77
IWR-1 inhibits epithelial-mesenchymal transition of colorectal cancer cells through suppressing Wnt/β-catenin signaling as well as survivin expression. Oncotarget (2015) 0.77
β-Cryptoxanthin Reduced Lung Tumor Multiplicity and Inhibited Lung Cancer Cell Motility by Downregulating Nicotinic Acetylcholine Receptor α7 Signaling. Cancer Prev Res (Phila) (2016) 0.75
Targeting the Mammalian Target of Rapamycin in Lung Cancer. Am J Med Sci (2016) 0.75
Drug safety advances from ICPE 2010. Ther Adv Drug Saf (2010) 0.75
Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer. PLoS One (2017) 0.75
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature (2008) 18.21
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol (2002) 17.41
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol (2004) 12.12
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 9.68
Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol (2007) 8.07
Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell (2003) 6.76
Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med (2001) 4.56
The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr Biol (2000) 4.24
Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest (2003) 4.06
An expanding role for mTOR in cancer. Trends Mol Med (2005) 3.40
Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol (2004) 3.17
Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res (2007) 2.81
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res (2002) 2.50
Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst (2003) 2.31
A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest (2002) 2.19
Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest (2006) 2.15
Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A (2006) 2.10
Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst (2005) 2.09
Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis (2005) 2.02
Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res (2005) 2.01
Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res (2006) 1.94
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis (2004) 1.92
PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol (2005) 1.67
Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J (2006) 1.67
Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol (2005) 1.64
Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res (2002) 1.61
Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem (2005) 1.59
Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat Res (2008) 1.49
Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res (2007) 1.46
Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Res (2004) 1.45
Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev (2003) 1.42
Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. J Cancer Res Clin Oncol (2001) 1.41
Cruciferous vegetable consumption and lung cancer risk: a systematic review. Cancer Epidemiol Biomarkers Prev (2009) 1.38
Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res (2003) 1.38
Relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines. Cancer Res (1989) 1.38
Nicotine induces multi-site phosphorylation of Bad in association with suppression of apoptosis. J Biol Chem (2004) 1.37
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene (2004) 1.28
Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J Biol Chem (2004) 1.28
A phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol Biomarkers Prev (2006) 1.25
Expression of ErbB receptors and mucins in the airways of long term current smokers. Thorax (2004) 1.18
Indole-3-carbinol inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo(a)pyrene-induced lung tumorigenesis in A/J mice and modulates carcinogen-induced alterations in protein levels. Cancer Res (2007) 1.07
Efficacy of polyphenon E, red ginseng, and rapamycin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice. Neoplasia (2006) 1.06
Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. Chem Res Toxicol (2004) 1.01
A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. PLoS One (2009) 1.01
Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3' kinase. Cancer Res (1997) 0.99
Efficacy of deguelin and silibinin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice. Neoplasia (2005) 0.95
The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer Prev Res (Phila) (2009) 0.93
Indole-3-carbinol: anticarcinogen or tumor promoter in brassica vegetables? Chem Biol Interact (1998) 0.93
Dose-dependent inhibition of tobacco smoke carcinogen-induced lung tumorigenesis in A/J mice by indole-3-carbinol. Cancer Prev Res (Phila) (2008) 0.93
K-ras mutations in lung tumors from A/J and A/J x TSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. Carcinogenesis (1995) 0.88
Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure. Carcinogenesis (2008) 0.87
The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer (2008) 0.85
Combinations of N-Acetyl-S-(N-2-Phenethylthiocarbamoyl)-L-Cysteine and myo-inositol inhibit tobacco carcinogen-induced lung adenocarcinoma in mice. Cancer Prev Res (Phila) (2008) 0.84
Dose-response study of myo-inositol as an inhibitor of lung tumorigenesis induced in A/J mice by benzo. Cancer Lett (2001) 0.84
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer (2011) 4.37
Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest (2003) 4.06
Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) (2010) 3.86
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat (2007) 3.78
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther (2002) 3.55
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 3.32
Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat (2002) 2.95
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 2.11
Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis (2005) 2.02
Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J Am Chem Soc (2003) 1.83
Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep (2009) 1.73
PTEN hamartoma tumor syndromes. Eur J Hum Genet (2008) 1.72
Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab (2013) 1.68
Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol (2005) 1.64
Targeting Akt in cancer therapy. Anticancer Drugs (2007) 1.57
Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res (2007) 1.46
Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Res (2004) 1.45
Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res (2004) 1.43
Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res (2003) 1.38
Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res (2006) 1.38
Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med (2003) 1.34
An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol (2005) 1.33
Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer. Cancer Prev Res (Phila) (2011) 1.27
Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. Cancer Res (2005) 1.22
Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy. Autophagy (2007) 1.21
Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. Cancer Res (2008) 1.20
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol Cancer Ther (2006) 1.14
Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms. J Biol Chem (2007) 1.14
Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death. Cancer Res (2005) 1.14
A novel classification of lung cancer into molecular subtypes. PLoS One (2012) 1.13
Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS (2008) 1.12
Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila) (2013) 1.08
Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet (2012) 1.04
A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. PLoS One (2009) 1.01
LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol (2009) 0.94
The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer Prev Res (Phila) (2009) 0.93
Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clin Cancer Res (2006) 0.93
Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer. Oncotarget (2014) 0.92
The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opin Investig Drugs (2004) 0.91
Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance. PLoS One (2011) 0.89
Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice. Neoplasia (2008) 0.88
Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer (2006) 0.87
A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice. Carcinogenesis (2011) 0.87
Induction of preneoplastic lung lesions in guinea pigs by cigarette smoke inhalation and their exacerbation by high dietary levels of vitamins C and E. Carcinogenesis (2004) 0.87
Nelfinavir inhibits maturation and export of herpes simplex virus 1. J Virol (2014) 0.86
Lipid molecules induce p38α activation via a novel molecular switch. J Mol Biol (2012) 0.83
Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo. Chest (2004) 0.81
PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development. Crit Rev Oncol Hematol (2007) 0.79
Modulating protein kinase C (PKC) to increase the efficacy of chemotherapy: stepping into darkness. Drug Resist Updat (2003) 0.79
Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations. Clin Lung Cancer (2013) 0.78
Impact of HIV on lung tumorigenesis in an animal model. AIDS (2015) 0.78
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. Mol Cancer Ther (2011) 0.78
PPARgamma agonists follow an unknown TRAIL in lung cancer. Cancer Biol Ther (2007) 0.78
Management of reproductive health in Cowden syndrome complicated by endometrial polyps and breast cancer. Obstet Gynecol (2013) 0.77
Starting with the ABCs: Akt in breast cancer. Mol Cancer Ther (2011) 0.77
Disparities in cancer funding. Science (2004) 0.77
Targeting aberrant signal transduction pathways in lung cancer. Cancer Biol Ther (2004) 0.77
Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2004) 0.75
Gefitinib for refractory advanced non-small-cell lung cancer. Lancet (2006) 0.75
Germline PTEN mutations as a cause of early-onset endometrial cancer. J Clin Oncol (2008) 0.75
Using immunotherapy to target EGF in patients with NSCLC. Cancer Biol Ther (2006) 0.75
A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer. Cancer Biol Ther (2005) 0.75
Overestimating the influence of the 1999 WHO classification of lung tumors on survival in bronchioloalveloar carcinoma. J Clin Oncol (2006) 0.75